Eledon Pharmaceuticals, Inc.
ELDNHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. At a $245.4M market cap, Eledon Pharmaceuticals, Inc. ranks as a micro-cap company within healthcare. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Market Cap
$245.4M
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-3.92
EPS (TTM)
$-0.90
EPS (Fwd)
$-0.77
ROE
-110.7%
ROA
-39.0%
Cash
$88.8M
Total Debt
$467,000
Free CF
-$45.1M
52W Change
12.7%
Annual Financials
Cash vs Debt
Where ELDN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ELDN finished 9.67% below its 150-day moving average ($3.31) and 2.75% above its 200-day moving average ($2.91). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ELDN overbought or oversold?
At the September 3, 2026 close, ELDN's RSI(14) was 16.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Eledon Pharmaceuticals, Inc. holds $88.8M in cash against $467K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$45.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -110.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, ELDN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ELDN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.